Vasogen Inc.

Contact:

Glenn Neumann, Investor Relations
2505 Meadowvale Blvd.
Mississauga, ON, Canada L5N 5S2
tel: (905) 817-2004  fax: (905) 569-9231
www.vasogen.com / investor@vasogen.com


--------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE

                    Vasogen to Present at the Canaccord Adams
                           26th Annual Summer Seminar

Mississauga, Ontario (August 2, 2006) -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a
leader in the research and commercial development of technologies targeting the
chronic inflammation underlying cardiovascular and neurological disease, today
announced that its President and Chief Executive Officer, David Elsley, will
present a Company overview at the Canaccord Adams 26th Annual Summer Seminar on
Wednesday, August 9, at 9:00 a.m. ET at the Boston Marriott Long Wharf Hotel.

A live audio web cast and slide presentation of the event can be accessed
through Vasogen's Web site at: www.vasogen.com. An archived replay will be
                               ---------------
available following the presentation.

About Vasogen:
Vasogen is focused on the research and commercial development of technologies
targeting the chronic inflammation underlying cardiovascular and neurological
disease. The recently completed international 2,400-patient ACCLAIM trial
assessed the impact of the Celacade technology on reducing the risk of mortality
and morbidity in patients with advanced heart failure. Full results for the
ACCLAIM study are scheduled to be presented at the World Congress of Cardiology
2006, being held in Barcelona, Spain, from September 2 to 6 and at the 10th
Annual Scientific Meeting of the Heart Failure Society of America being held in
Seattle, Washington, from September 10 to 13, 2006. Vasogen is also developing a
new class of drugs for the treatment of neuro-inflammatory and neuro-vascular
disorders. VP025, which is entering phase II clinical development, is the lead
product candidate from this new class of drugs.


Certain  statements  contained in this press  release and upcoming  presentation
constitute "forward-looking  statements" within the meaning of the United States
Private  Securities  Litigation  Reform Act of 1995. These  statements  include,
without  limitation,  summary  statements  relating  to  initial  results of the
ACCLAIM  trial in patients  with  chronic  heart  failure,  plans to advance the
development  of  Celacade,  statements  concerning  our  partnering  activities,
strategy,  future  operations,   future  financial  position,  future  revenues,
projected  costs,  prospects,  plans and  objectives of  management.  Except for
results on the primary endpoint,  initial results disclosed are based on initial
data  analyzed  and may not be  confirmed  upon full  analysis  of the  detailed
results of the ACCLAIM trial and additional  information  relating to safety and
efficacy of Celacade may be discovered  upon further  analysis of trial data and
upon further  review and analysis of additional  trial data. In some cases,  you
can identify  forward-looking  statements by terminology such as "may",  "will",
"should",   "expects",   "plans",   "anticipates",    "believes",   "estimated",
"predicts", "potential", "continue", "intends", "could", or the negative of such
terms or other  comparable  terminology.  You should not place undue reliance on
our  forward-looking  statements  which are subject to a multitude  of risks and
uncertainties that could cause actual results, future circumstances or events to
differ materially from those projected in the forward-looking statements.  These
risks  include,  but are not limited to, the outcome of further  analysis of the
ACCLAIM  trial  results,  the  requirement  or  election  to conduct  additional
clinical  trials,  risks  associated  with  the  outcome  of  our  research  and
development programs,  the adequacy,  timing and results of our clinical trials,
the need for additional  capital and the effect of capital market conditions and
other factors on capital  availability,  the potential  dilutive  effects of any
financing,  including  the  convertible  notes we issued in  October  2005,  the
regulatory  approval process,  competition,  securing and maintaining  corporate
alliances, market acceptance of our products, the availability of government and
insurance   reimbursements  for  our  products,  the  strength  of  intellectual
property,   reliance  on  subcontractors  and  key  personnel,   losses  due  to
fluctuations in the  U.S.-Canadian  exchange rate, and other risks detailed from
time to time in our  public  disclosure  documents  or  other  filings  with the
Canadian and U.S. securities  commissions or other securities regulatory bodies.
Additional risks and uncertainties  relating to our Company and our business can
be found in the "Risk Factors"  section of our Annual  Information Form and Form
40F for the year ended November 30, 2005 as well as in our later public filings.
The  forward-looking  statements are made as of the date hereof, and we disclaim
any intention and have no  obligation or  responsibility,  except as required by
law, to update or revise any forward-looking statements,  whether as a result of
new  information,  future  events  or  otherwise.  Unless  otherwise  indicated,
numerical values indicating the statistical significance ("p-values") of results
included in this document are based on analyses that do not account for endpoint
multiplicity.